ArticleBMJ open2016
Long-term financing needs for HIV control in sub-Saharan Africa in 2015-2050: a modelling study.
Article in BMJ open, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Integrating HIV services and other health services: A systematic review and meta-analysis.PLoS medicine · 2021Pooled it
- Physical activity and HIV in sub-Saharan Africa: a systematic review of correlates and levels.African health sciences · 2018Pooled it
- Innovative financing for HIV response in sub-Saharan Africa.Journal of global health · 2016Pooled it
- Trial
- The impact of community health worker-led home delivery of antiretroviral therapy on virological suppression: a non-inferiority cluster-randomized health systems trial in Dar es Salaam, Tanzania.BMC health services research · 2017Trial
- Exploration for the Priority of HIV Intervention: Modelling Health Impact and Cost-Effectiveness - Six Cities, Eastern China, 2019-2028.China CDC weekly · 2024Article
- The emergence and circulation of human immunodeficiency virus (HIV)-1 subtype C.Journal of medical microbiology · 2024Article
- Article
- Getting resources to those who need them: the evidence we need to budget for underserved populations in sub-Saharan Africa.Journal of the International AIDS Society · 2021Article
- Pandemics and Burden of Stroke and Epilepsy in Sub-Saharan Africa: Experience from a Longstanding Health Programme.International journal of environmental research and public health · 2021Review
- Assessing the costs and efficiency of HIV testing and treatment services in rural Malawi: implications for future "test and start" strategies.BMC health services research · 2020Article
- Innovative financing to fund surgical systems and expand surgical care in low-income and middle-income countries.BMJ global health · 2020Review
- The short-term effects of the implementation of the "Treat All" guidelines on ART service delivery costs in Namibia.PloS one · 2020Article
- Ending TB in Southeast Asia: current resources are not enough.BMJ global health · 2020Review
- Pepfar 3.0's HIV testing policy in Côte d'Ivoire (2014 to 2018): fragmentation, acceleration and disconnection.Journal of the International AIDS Society · 2019Article
- Article
- Mathematical modelling to inform 'treat all' implementation in sub-Saharan Africa: a scoping review.Journal of virus eradication · 2018Article
- Policy makers, the international community and the population in the prevention and treatment of diseases: case study on HIV/AIDS.Health economics review · 2017Article
- Criteria for prioritization of HIV programs in Viet Nam: a discrete choice experiment.BMC health services research · 2017Article
- Can differentiated care models solve the crisis in HIV treatment financing? Analysis of prospects for 38 countries in sub-Saharan Africa.Journal of the International AIDS Society · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesTo estimate the present value of current and future funding needed for HIV treatment and prevention in 9 sub-Saharan African (SSA) countries that account for 70% of HIV burden in Africa under different scenarios of intervention scale-up. To analyse the gaps between current expenditures and funding obligation, and discuss the policy implications of future financing needs.
designWe used the Goals module from Spectrum, and applied the most up-to-date cost and coverage data to provide a range of estimates for future financing obligations. The four different scale-up scenarios vary by treatment initiation threshold and service coverage level. We compared the model projections to current domestic and international financial sources available in selected SSA countries.
resultsIn the 9 SSA countries, the estimated resources required for HIV prevention and treatment in 2015-2050 range from US$98 billion to maintain current coverage levels for treatment and prevention with eligibility for treatment initiation at CD4 count of <500/mm(3) to US$261 billion if treatment were to be extended to all HIV-positive individuals and prevention scaled up. With the addition of new funding obligations for HIV--which arise implicitly through commitment to achieve higher than current treatment coverage levels--overall financial obligations (sum of debt levels and the present value of the stock of future HIV funding obligations) would rise substantially.
conclusionsInvesting upfront in scale-up of HIV services to achieve high coverage levels will reduce HIV incidence, prevention and future treatment expenditures by realising long-term preventive effects of ART to reduce HIV transmission. Future obligations are too substantial for most SSA countries to be met from domestic sources alone. New sources of funding, in addition to domestic sources, include innovative financing. Debt sustainability for sustained HIV response is an urgent imperative for affected countries and donors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.